Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials

Published:2022-11-07 Issue:3 Volume:33 Page:272-288
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Cui Ying¹,Dong Gaohong²^ORCID,Kuan Pei Fen³,Huang Bo⁴^ORCID

Affiliation:

1. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA

2. BeiGene, Ridgefield Park, NJ, USA

3. Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, USA

4. Pfizer Inc, Groton, CT, USA

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2022.2141769

Reference38 articles.

1. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components

2. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

3. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

4. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials

5. Cui, Y., and B. Huang. WINS: The R WINS Package. 2022. https://cran.r-project.org/web/packages/WINS/index.html.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining estimand for the win ratio: Separate the true effect from censoring;Clinical Trials;2024-07-30

2. Restricted Time Win Ratio: From Estimands to Estimation;Statistics in Biopharmaceutical Research;2024-04-26

3. Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry;Thrombosis and Haemostasis;2023-08-25

4. Dissecting the restricted mean time in favor of treatment;Journal of Biopharmaceutical Statistics;2023-05-24

5. The stratified win statistics (win ratio, win odds, and net benefit);Pharmaceutical Statistics;2023-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3